<DOC>
	<DOCNO>NCT01339650</DOCNO>
	<brief_summary>This Phase 1 , dose escalation trial evaluate tolerability , pharmacokinetics , pharmacodynamics ABT-767 subject advance Breast Cancer 1 2 gene ( BRCA1 BRCA2 ) -mutated solid tumor high grade serous ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Study ABT-767 Subjects With Breast Cancer 1 Breast Cancer 2 ( BRCA 1 BRCA 2 ) Mutations Solid Tumors High Grade Serous Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>This Phase 1 , dose escalation trial evaluate tolerability , pharmacokinetics , pharmacodynamics ABT-767 subject advance BRCA1 BRCA2-mutated solid tumor high grade serous ovarian , fallopian tube , primary peritoneal cancer . ABT-767 potent oral inhibitor enzyme poly ( ADP-ribose ) polymerase 1 2 ( PARP-1 PARP-2 ) . Malignancies deficiencies homologous repair , BRCA-1 BRCA-2 deficient tumor , dependent PARP deoxyribonucleic acid ( DNA ) repair normal cell , thus , think sensitive PARP inhibition . The study design single-arm dose escalation study determine dose-limiting toxicity , maximum tolerate dose recommended Phase 2 dose ( RPTD ) orally administer ABT-767 subject BRCA mutation malignancy . In order evaluate safety tolerability ABT-767 RPTD , 20 additional subject enrol expanded safety cohort consist BRCA1- BRCA2-mutated Breast cancer Ovarian cancer .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>1 . Subject must ≥ 18 year age . 2 . Subjects must histological cytological confirmation locally advance metastatic solid tumor , document Breast Cancer Gene 1 2 mutation , high grade serous ovarian , fallopian tube , primary peritoneal cancer . 3 . Subject Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 2 4 . Subjects must adequate hematologic , renal , hepatic function follow : . Bone Marrow : Absolute neutrophil count ( ANC ≥ 1,500/mm3 ( 1.5 ≥ 109/L ) ; Platelets ≥ 100,000/mm3 ( 100 ≥ 109/L ) ; Hemoglobin ≥ 9.0 g/dL ( 1.4 mmol/L ) ( hemoglobin unsupported transfusion b . Subject adequate renal function demonstrate serum creatinine value ≤ 1.5 x upper limit normal ( ULN ) either estimate creatinine clearance value ≥ 50 mL/min determine CockcroftGault formula creatinine clearance value ≥ 50 mL/min/1.73 m2 base 24hour urine collection c. Subject adequate liver function demonstrate serum bilirubin ≤ 1.5 x ULN Aspartate Aminotransferase ( AST ) Alanine Transaminase ( ALT ) ≤ 2.5 ULN . For subject liver metastasis , AST ALT &lt; 5 x ULN . Partial Thromboplastin Time ( PTT ) must ≤ ULN INR &lt; 1.5 . Subjects anticoagulant ( Coumadin ) allow study PTT International Normalize Ratio ( INR ) determine Investigator . 5 . Women childbearing potential must agree use adequate contraception prior study entry , duration study participation , 90 day follow completion therapy . Women childbearing potential must negative serum pregnancy test within 21 day prior initiation treatment negative urine pregnancy test first day study drug administration . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 1 . Expanded cohort : Subject previously receive poly ( ADPribose ) polymerase ( PARP ) inhibitor . 2 . Subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , biologic investigational therapy within period 28 day 5 half life ( whichever short ) prior Study Day 1 . 3 . Subject known Central Nervous System ( CNS ) metastases . 4 . Subject unresolved toxicity prior anticancer therapy , define Common Terminology Criteria Adverse Events ( CTCAE v 4.0 ) grade 2 high clinically significant toxicity ( exclude alopecia ) . 5 . Subject major surgery within 28 day prior Study Day 1 . 6 . Clinically significant uncontrolled condition ( ) medical condition opinion study investigator place subject unacceptably high risk toxicity . 7 . Psychiatric illness/social situation would limit compliance study requirement . 8 . Lactating pregnant female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>BRCA 1 BRCA 2 Mutations</keyword>
	<keyword>Breast Cancer 1</keyword>
	<keyword>Breast Cancer 2</keyword>
	<keyword>High Grade Serous Ovarian , Fallopian Tube , Primary Peritoneal Cancers</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>